<DOC>
	<DOCNO>NCT00149383</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability , efficacy adjunctive rosiglitazone treatment uncomplicated P.falciparum malaria .</brief_summary>
	<brief_title>Safety Efficacy Study Adjunctive Rosiglitazone Treatment Uncomplicated Falciparum Malaria</brief_title>
	<detailed_description>Study Rationale : Evidence suggest PPAR-RXR agonist ( rosiglitazone ) use adjunctive therapy P. falciparum malaria infection may increase phagocytic clearance P. falciparum malaria , modulate deleterious inflammatory response decrease sequestration malaria parasites vital organ . They may therefore represent novel immunomodulatory treatment approach P. falciparum malaria . Study Objectives : 1 ) To examine vivo effect rosiglitazone rapidity clearance P. falciparum parasitemia fever patient non-severe P. falciparum infection 2 ) To assess safety tolerability adjunctive rosiglitazone treatment non-severe case P. falciparum infection . Primary Outcomes : Time clearance P. falciparum parasitemia Study Design : Randomized double blind placebo-controlled trial . Intervention : Standard antimalarial treatment ( atovaquone/proguanil ) patient combine adjuvant rosiglitazone treatment ( 8mg per day ) placebo . Setting : Hospital Tropical Diseases Mahidol University , Thailand . Participants : 140 patient non-severe P. falciparum infection . Follow-up : 28 day</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Microscopically confirm P.falciparum infection Age &gt; 18 year Able tolerate oral therapy Able give inform consent Fulfillment WHO criteria severe/cerebral malaria Prior treatment thiazolidinedione Allergy rosiglitazone History diabetes mellitus History severe/decompensated liver disease ALT level &gt; 2.5 time normal Current treatment congestive heart failure Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>randomize control trial</keyword>
	<keyword>malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>thiazolidinediones</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>atovaquone-proguanil</keyword>
</DOC>